ArticleFrontiers in bioengineering and biotechnology2025
Evaluation of FeMnN alloy bioresorbable flow diverters in the rabbit elastase induced aneurysm model.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bioresorbable flow-diverters for cerebral aneurysms: a systematic review.Neuroradiology · 2026Pooled it
- Defining biomaterial-driven design principles for bioabsorbable flow diverters: current state and perspectives.Bioactive materials · 2027Review
- Magnetizable flow diverters can magnetically capture and retain endothelial cells to promote healing in rabbit arteries.Journal of neuroradiology = Journal de neuroradiologie · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Introduction: Flow diverters are specialized stents used to treat intracranial aneurysms. Bioresorbable flow diverters (BRFDs) have been proposed as the next-generation of flow diverter technology. BRFDs aim to occlude and heal the aneurysm before safely dissolving into the body, mitigating complications associated with the permanent presence of conventional flow diverters. We previously prototyped BRFDs using an iron-manganese-nitrogen (FeMnN) alloy and demonstrated their flow diversion functionality, radial strength, bioresorbability, and MRI compatibility in benchtop tests. In the current work, we investigated their aneurysm occlusion efficacy Methods: Elastase induced aneurysms were created in seven rabbits and BRFDs were deployed over the aneurysms for 3 months. Aneurysm occlusion efficacy and the biological response was assessed via angiography, gross dissection microscopy, and histology. Results: The BRFDs failed to occlude the aneurysms in 5/7 rabbits at the 3-month endpoint. The bioresorbable wires appeared to resorb too rapidly and fragment away from the aneurysm neck prior to becoming entirely encased in tissue and completely occluding the aneurysm. In 3/7 rabbits, some FeMnN wires remained over the aneurysm neck that were encased in tissue, partially covering the aneurysm neck. Histological analysis revealed that the wires, when present, were a suitable substrate over which tissue could develop. Therefore, we attribute the poor aneurysm occlusion efficacy to mechanical failure rather than an impaired biological healing response. Conclusion: The FeMnN BRFDs degraded too rapidly to effectively treat the rabbit elastase induced aneurysms. Future work will focus on developing BRFDs out of materials with a delayed resorption rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.